India to Colombia: Rituximab Export Trade Route

The India to Colombia Rituximab corridor is one of India's established pharmaceutical export routes, with 12 shipments documented worth a combined $1.2M USD. The route is dominated by RELIANCE LIFE SCIENCES PRIVATE LIMITED, which alone accounts for roughly 89% of all export value, reflecting the consolidated nature of India's rituximab manufacturing sector.

Across 2 active suppliers, the average shipment value stands at $97.9K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (65%) and air (15%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during July–September, with an average transit time of 21 days port-to-port. The route has recorded an annual growth rate of 24.8%, placing it at rank #2 among India's top rituximab export destinations globally.

On the import side, key buyers of Indian rituximab in Colombia include LABORATORIOS LEGRAND S A, LABORATORIOS LEGRAND S.A, LABORATORIOS LEGRAND S,A and 2 others. LABORATORIOS LEGRAND S A is the single largest importer with 5 shipments valued at $583.5K USD.

India's rituximab exports to Colombia are driven primarily by a handful of large-scale manufacturers. RELIANCE LIFE SCIENCES PRIVATE LIMITED with 10 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 2 active exporters signals a competitive but concentrated market — buyers in Colombia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — RELIANCE LIFE SCIENCES PRIVATE LIMITED, RELIANCE LIFE SCIENCES PRIVATE LIMITED — together account for 100% of total trade value on this route. The average shipment value of $97.9K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as rituximab 500 mg iximab 500 mg batch d and rituximab 500mg (iximab 500mg) batch no.rmv1b24017, suggesting that buyers in Colombia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, LABORATORIOS LEGRAND S A is the largest importer with 5 shipments worth $583.5K USD — representing 50% of all rituximab imports from India on this route.